Conflicts of Interest The study was initiated and carried out independently by the authors. Apart from leasing of the Starlux 1540 nm fractionated hand piece from Dalton Medical, The Netherlands, the study was accomplished without influence or any form of investigator compensation from Palomar or Dalton Medical, the supplier of the device.
Nonablative fractional laser resurfacing for the treatment of scars and grafts after Mohs micrographic surgery: a randomized controlled trial
Article first published online: 4 JUL 2012
© 2012 The Authors. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 27, Issue 8, pages 997–1002, August 2013
How to Cite
Verhaeghe, E., Ongenae, K., Dierckxsens, L., Bostoen, J. and Lambert, J. (2013), Nonablative fractional laser resurfacing for the treatment of scars and grafts after Mohs micrographic surgery: a randomized controlled trial. Journal of the European Academy of Dermatology and Venereology, 27: 997–1002. doi: 10.1111/j.1468-3083.2012.04639.x
Funding sources This work is supported by a grant of the ‘Klinisch Onderzoeksfonds’ of Ghent University Hospital.
- Issue published online: 17 JUL 2013
- Article first published online: 4 JUL 2012
- Received: 2 March 2012; Accepted: 8 June 2012
Background Mohs micrographic surgery is a tissue sparing surgical technique for removal of skin cancer. To optimize the cosmetic result of scars and skin grafts after surgery non invasive procedures as non-ablative fractional laser (NAFL) resurfacing are attractive.
Objective To evaluate efficacy and safety of 1540 nm NAFL in the treatment of scars and skin grafts after Mohs micrographic surgery.
Methods An intra-individual randomized controlled trial (RCT) with split lesion design and single blinded outcome evaluations. Patients receive four treatments at monthly interval with NAFL [StarLux-300 with Lux 1540 nm fractional handpiece (Palomar technologies)]. Primary endpoint to evaluate efficacy is a blinded on site visual and palpable Physician Global Assessment (PhGA). Adverse event and pain registration are used to evaluate safety. Patient’s global assessment (PGA) and skin reflectance measurements are secondary endpoints.
Results The PhGA score comparing the treated to the untreated control side of 24 patients is significant different 1 (P = 0.009) and 3 (P = 0.001) months after treatment (Wilcoxon signed rank test). Patients experienced mild to moderate pain. Four days after the treatments patients reported erythema (67%), oedema (31%), crusts (22%), burning sensation (14%), purpura (9%) and vesicles (4%). No long term adverse events are reported. PGA is significant different 1 (P < 0. 001) and 3 months (P < 0. 001) after the last treatment. Skin reflectance do not show significant difference.
Conclusion This study shows that nonablative 1540 nm fractional laser is a safe and effective treatment for the improvement of scars and grafts after Mohs surgery.